As the U.S. stock market navigates a complex landscape of fluctuating earnings reports and tariff developments, investors are keenly observing how these factors influence broader economic health. In such an environment, growth companies with high insider ownership can offer unique insights into potential resilience and alignment of interests between management and shareholders.
Name | Insider Ownership | Earnings Growth |
Victory Capital Holdings (VCTR) | 10.1% | 32.4% |
Super Micro Computer (SMCI) | 13.9% | 36.3% |
Prairie Operating (PROP) | 34.4% | 80.8% |
Niu Technologies (NIU) | 37.2% | 88.1% |
FTC Solar (FTCI) | 23.1% | 66.9% |
Credo Technology Group Holding (CRDO) | 11.7% | 36.4% |
Cloudflare (NET) | 10.6% | 45.8% |
Chemung Financial (CHMG) | 19.9% | 78.3% |
Atour Lifestyle Holdings (ATAT) | 22.6% | 23.5% |
Astera Labs (ALAB) | 12.8% | 45.6% |
Click here to see the full list of 182 stocks from our Fast Growing US Companies With High Insider Ownership screener.
Let's uncover some gems from our specialized screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Bridgewater Bancshares, Inc. is the bank holding company for Bridgewater Bank, offering a range of banking products and services in the United States with a market cap of $418.56 million.
Operations: The company generates revenue of $119.31 million from its banking products and services in the United States.
Insider Ownership: 20.6%
Bridgewater Bancshares has demonstrated robust growth, with recent earnings showing net income rising to US$11.52 million from US$8.12 million a year ago. The company is trading below analyst price targets and is expected to see annual profit growth of 21.8%, outpacing the broader market's 14.7%. Despite no substantial insider buying recently, the company has been active in share repurchases and added to multiple Russell Growth Indexes, signaling strong institutional interest.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Prothena Corporation plc is a late-stage clinical biotechnology company that develops novel therapies for diseases caused by protein dysregulation in the United States, with a market cap of approximately $373.58 million.
Operations: Prothena focuses on the discovery and development of innovative treatments for diseases linked to protein dysregulation in the U.S., with revenue segments currently not specified.
Insider Ownership: 20.2%
Prothena has faced significant challenges, with recent earnings showing a steep decline in revenue to US$4.42 million from US$132.01 million year-over-year and a net loss of US$125.77 million for Q2 2025. Despite this, the company is trading significantly below its estimated fair value and is expected to achieve profitability within three years, with forecasted annual revenue growth of 53.8%. The discontinuation of birtamimab development aims to reduce cash burn substantially by year's end.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Tuya Inc. operates as an AI cloud platform service provider in China and internationally, with a market cap of approximately $1.41 billion.
Operations: The company's revenue segment is primarily derived from Internet Software & Services, totaling $311.64 million.
Insider Ownership: 29.8%
Tuya's recent financial performance shows a turnaround, with Q1 2025 earnings reaching US$11.02 million compared to a net loss the previous year. Insider ownership remains high, and analysts expect significant earnings growth of 39.9% annually, outpacing the US market average. Although revenue is projected to grow at 12% per year, it lags behind the company's earnings growth rate. Recent board changes and bylaw amendments aim to enhance governance and align with regulatory updates.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Discover if Bridgewater Bancshares might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。